Heart Failure: Trends in the Northeastern US

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Heart Failure: Trends in the Northeastern US

ReachMD Healthcare Image

Cardiologists across the country deal with heart failure every day. Here’s how this condition is impacting the Northeast.


    VERQUVO is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for HF or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.



    Females of reproductive potential: Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after stopping treatment. Do not administer VERQUVO to a pregnant female because it may cause fetal harm.

    ● VERQUVO is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators
    ● VERQUVO is contraindicated in pregnancy.
    ● Embryo-Fetal Toxicity: Based on data from animal reproduction studies, VERQUVO may cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to a fetus. Obtain a pregnancy test before the start of treatment. Advise females of reproductive potential to use effective contraception during treatment with VERQUVO and for at least one month after the final dose.
    ● In a clinical trial, the most commonly observed adverse events with VERQUVO vs placebo, occurring at a frequency ≥5%, were hypotension (16% vs 15%) and anemia (10% vs 7%).
    ● Concomitant use of VERQUVO with PDE-5 inhibitors is not recommended due to the potential for hypotension.
    ● There are no data on the presence of vericiguat in human milk, the effects on the breastfed infant, or effects on milk production. Because of the potential for serious adverse reactions in breastfed infants from VERQUVO, advise women not to breastfeed during treatment with VERQUVO.

    Before prescribing VERQUVO, please read the accompanying Prescribing Information, including the Boxed Warning about embryo-fetal toxicity. The Medication Guide also is available.

  • Overview

    Heart failure continues to be a major healthcare challenge in the US1, including in the Northeast. Cardiologist Dr. Norbert Moskovits is here to walk us through some ways heart failure is having an impact on the Northeast and VERQUVO® (vericiguat) as a treatment option for appropriate patients with chronic heart failure.

    1. Heidenreich PA et al. Circ Heart Fail. 2013; 606–619.

Schedule29 May 2023